Prognostic value of prostate volume in non-muscle invasive bladder cancer

Abstract There is evidence that a history of benign prostatic hyperplasia increases the incidence of bladder cancer, and treatment with 5-alpha reductase inhibitor or androgen deprivation therapy reduces recurrence of non-muscle invasive bladder cancer. We aimed to evaluate whether prostate volume a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Won Sik Ham, Jee Soo Park, Won Sik Jang, Young Deuk Choi, Jongchan Kim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a2f8c1b853e0440ba848a6d93098b682
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2f8c1b853e0440ba848a6d93098b682
record_format	dspace
spelling	oai:doaj.org-article:a2f8c1b853e0440ba848a6d93098b6822021-12-02T15:14:47ZPrognostic value of prostate volume in non-muscle invasive bladder cancer10.1038/s41598-021-98045-12045-2322https://doaj.org/article/a2f8c1b853e0440ba848a6d93098b6822021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98045-1https://doaj.org/toc/2045-2322Abstract There is evidence that a history of benign prostatic hyperplasia increases the incidence of bladder cancer, and treatment with 5-alpha reductase inhibitor or androgen deprivation therapy reduces recurrence of non-muscle invasive bladder cancer. We aimed to evaluate whether prostate volume affects its prognosis. We reviewed medical records of men who underwent transurethral resection of bladder tumor due to non-muscle invasive bladder cancer from January 2012 to December 2017. Patients were divided into two groups based on prostate volume measured by computed tomography (group 1: 264 patients with ≤ 30 mL, group 2: 124 patients with > 30 mL). Propensity score matching analysis was used for adjust selection bias, and then assessed recurrence-free survival and progression-free survival. With a median follow up duration of 52 months, group 1 showed higher 5-year recurrence-free and progression-free survival (69.3% vs 47.0%, p = 0.001; 96.7% vs 87.7%, p = 0.002). Further, cox-regression analysis showed that tumor size (HR = 1.292 p < 0.001), multifocal tumor (HR = 1.993, p < 0.001), adjuvant intravesical therapy (chemotherapy: HR = 0.580, p = 0.037 and bacillus Calmette–Guérin: HR = 0.542, p = 0.004) and prostate volume (HR = 2.326, p < 0.001) were significant predictors of recurrence-free survival. Prostate volume (HR = 2.886, p = 0.014) was also associated with PFS with age (HR = 1.043, p = 0.044) and tumor grade (HR = 3.822, p = 0.013). We conclude higher prostate volume is associated with worse recurrence and progression-free survival in non-muscle invasive bladder cancer.Won Sik HamJee Soo ParkWon Sik JangYoung Deuk ChoiJongchan KimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Won Sik Ham Jee Soo Park Won Sik Jang Young Deuk Choi Jongchan Kim Prognostic value of prostate volume in non-muscle invasive bladder cancer
description	Abstract There is evidence that a history of benign prostatic hyperplasia increases the incidence of bladder cancer, and treatment with 5-alpha reductase inhibitor or androgen deprivation therapy reduces recurrence of non-muscle invasive bladder cancer. We aimed to evaluate whether prostate volume affects its prognosis. We reviewed medical records of men who underwent transurethral resection of bladder tumor due to non-muscle invasive bladder cancer from January 2012 to December 2017. Patients were divided into two groups based on prostate volume measured by computed tomography (group 1: 264 patients with ≤ 30 mL, group 2: 124 patients with > 30 mL). Propensity score matching analysis was used for adjust selection bias, and then assessed recurrence-free survival and progression-free survival. With a median follow up duration of 52 months, group 1 showed higher 5-year recurrence-free and progression-free survival (69.3% vs 47.0%, p = 0.001; 96.7% vs 87.7%, p = 0.002). Further, cox-regression analysis showed that tumor size (HR = 1.292 p < 0.001), multifocal tumor (HR = 1.993, p < 0.001), adjuvant intravesical therapy (chemotherapy: HR = 0.580, p = 0.037 and bacillus Calmette–Guérin: HR = 0.542, p = 0.004) and prostate volume (HR = 2.326, p < 0.001) were significant predictors of recurrence-free survival. Prostate volume (HR = 2.886, p = 0.014) was also associated with PFS with age (HR = 1.043, p = 0.044) and tumor grade (HR = 3.822, p = 0.013). We conclude higher prostate volume is associated with worse recurrence and progression-free survival in non-muscle invasive bladder cancer.
format	article
author	Won Sik Ham Jee Soo Park Won Sik Jang Young Deuk Choi Jongchan Kim
author_facet	Won Sik Ham Jee Soo Park Won Sik Jang Young Deuk Choi Jongchan Kim
author_sort	Won Sik Ham
title	Prognostic value of prostate volume in non-muscle invasive bladder cancer
title_short	Prognostic value of prostate volume in non-muscle invasive bladder cancer
title_full	Prognostic value of prostate volume in non-muscle invasive bladder cancer
title_fullStr	Prognostic value of prostate volume in non-muscle invasive bladder cancer
title_full_unstemmed	Prognostic value of prostate volume in non-muscle invasive bladder cancer
title_sort	prognostic value of prostate volume in non-muscle invasive bladder cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a2f8c1b853e0440ba848a6d93098b682
work_keys_str_mv	AT wonsikham prognosticvalueofprostatevolumeinnonmuscleinvasivebladdercancer AT jeesoopark prognosticvalueofprostatevolumeinnonmuscleinvasivebladdercancer AT wonsikjang prognosticvalueofprostatevolumeinnonmuscleinvasivebladdercancer AT youngdeukchoi prognosticvalueofprostatevolumeinnonmuscleinvasivebladdercancer AT jongchankim prognosticvalueofprostatevolumeinnonmuscleinvasivebladdercancer
_version_	1718387589711396864

Prognostic value of prostate volume in non-muscle invasive bladder cancer

Ejemplares similares